Osteoporosis drug passes clinical trail

Osteoporosis drug passes clinical trail

Washington D.C. [USA], Apr. 10 : A new study provides reassuring information about the short-term and long-term safety of denosumab, a monoclonal antibody that is used to treat postmenopausal osteoporosis.

Adverse events that had been noted in a pivotal clinical trial in women age 60 to 90 years old treated for three years showed no tendency to increase after a further three years of treatment, the study showed.

In addition, women who crossed over from three years of placebo to three years of denosumab experienced no increase in adverse effects compared with women treated for the initial three years.

"All of this is consistent with an excellent safety and tolerability profile for denosumab treatment for osteoporosis," said Dr. Nelson Watts, lead author of the study results published in Journal of Bone and Mineral Research.

The authors noted that, especially in older women on long-term treatment, many if not all adverse events could be called "life events"--things that would have happened whether or not the person was participating in a clinical trial. (ANI)

Region: 
General: 

Popular Stories

Excessive usage of phones up neck and upper back pain

London [UK], April 16 : Dear parents, ask your kids... Read More

Restriction in trans fats leads to healthier communities: Study

Washington D.C. [U.S.A.], Apr. 15 : According to a... Read More

What is Aplastic Anaemia?

New Delhi [India], Apr. 14 : Ever wonder what would... Read More

A protein discovered to treat Inflammatory Bowel Disease

Washington D.C. [USA], April 14 : A new study... Read More